FDA Clearance Tracker · P250051
Juveena Hydrogel System
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 28, 2026
Approved
Time to decision
292 days
Received Dec 10, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250051
- Device name
- Juveena Hydrogel System
- Applicant
- Rejoni, Inc.
- Applicant location
- Bedford, MA
- Received
- Dec 10, 2025
- Decided
- Sep 28, 2026
- Decision
- Approved
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Barrier, absorbable, adhesion (MCN)
- Device class
- Class III
- Specialty
- Obstetrics & Gynecology
FDA's approval statement
As written in FDA's record.
Approval for Juveena® Hydrogel System. The Juveena® Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.The Rejoni Acorn Catheter is indicated to access the uterine cavity and deliver the Juveena® Hydrogel solution into the uterine cavity.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MCN. The earliest in FDA's data is P880047, decided Sep 15, 1989.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Rejoni, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K222798 · Decided Dec 16, 2022 · 91 days after receipt
Device type: Cannula, Manipulator/Injector, Uterine (LKF) · Obstetrics & Gynecology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.